AR125766A2 - Método para formular un polipéptido terapéutico de unión a pcsk9 - Google Patents
Método para formular un polipéptido terapéutico de unión a pcsk9Info
- Publication number
- AR125766A2 AR125766A2 ARP220101176A ARP220101176A AR125766A2 AR 125766 A2 AR125766 A2 AR 125766A2 AR P220101176 A ARP220101176 A AR P220101176A AR P220101176 A ARP220101176 A AR P220101176A AR 125766 A2 AR125766 A2 AR 125766A2
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- polypeptide
- pcsk9
- solution
- heavy chain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Método para formular un polipéptido terapéutico de unión a PCSK9, que es ventajoso en cuanto conserva determinados componentes. Las composiciones formuladas mediante el método son útiles en enfermedades, afecciones y trastornos relacionados con PCSK9. Reivindicación 1: Un método para formular un polipéptido terapéutico, caracterizado porque comprende a. un primer paso de concentración, donde el polipéptido se concentra en una primera solución; b. un primer paso de intercambio de solución, donde el polipéptido concentrado en la primera solución se intercambia en una segunda solución que comprende N-acetil arginina usando diafiltración; c. un segundo paso de concentración, donde el polipéptido se concentra en la segunda solución; d. un segundo paso de intercambio de solución, donde el polipéptido en la segunda solución concentrada se intercambia en una tercera solución que comprende N-acetil arginina usando diafiltración; y e. un tercer paso de concentración, donde el polipéptido se concentra en la tercera solución; donde el polipéptido terapéutico comprende un polipéptido de unión a PCSK9 que bloquea la unión de PCSK9 con LDLR y se selecciona del grupo que consiste en: i. un anticuerpo monoclonal que comprende una cadena pesada con una secuencia de aminoácidos de SEQ ID Nº 1 y una cadena ligera con una secuencia de aminoácidos de SEQ ID Nº 2 (evolocumab), o un fragmento de unión al antígeno de este; ii. un anticuerpo monoclonal que compite con evolocumab para la unión con PCSK9; iii. un anticuerpo monoclonal, que comprende: 1) un polipéptido de cadena pesada que comprende las siguientes regiones determinantes de complementariedad (CDR): una CDR1 de cadena pesada que es una CDR1 en SEQ ID Nº 14 o 16; una CDR2 de cadena pesada que es una CDR2 en SEQ ID Nº 14 o 16; una CDR3 de cadena pesada que es una CDR3 en SEQ ID Nº 14 o 16, y 2) un polipéptido de cadena ligera que comprende las CDR: una CDR1 de cadena ligera que es una CDR1 en SEQ ID Nº 15 o 17; una CDR2 de cadena ligera que es una CDR2 en SEQ ID Nº 15 o 17; y una CDR3 de cadena ligera que es una CDR3 en SEQ ID Nº 15 o 17; iv. un anticuerpo monoclonal que se une con al menos uno de los siguientes residuos de PCSK9, PCSK9 comprende una secuencia de aminoácidos de SEQ ID Nº 3: S153, D188, I189, Q190, S191, D192, R194, E197, G198, R199, V200, D224, R237, D238, K243, S373, D374, S376, T377, F379, I154, T187, H193, E195, I196, M201, V202, C223, T228, S235, G236, A239, G244, M247, I369, S372, C375, C378, R237, D238; v. un anticuerpo monoclonal que se une con PCSK9 en un epítopo en PCSK9 que se superpone con un epítopo que está unido por un anticuerpo que comprende: 1) una región variable de cadena pesada de la secuencia de aminoácidos de SEQ ID Nº 1; y 2) una región variable de cadena ligera de la secuencia de aminoácidos de SEQ ID Nº 2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762462266P | 2017-02-22 | 2017-02-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR125766A2 true AR125766A2 (es) | 2023-08-09 |
Family
ID=61617101
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180100397A AR110938A1 (es) | 2017-02-22 | 2018-02-20 | Formulaciones de evolocumab de alta concentración y baja viscosidad y métodos para elaborarlas |
ARP220101176A AR125766A2 (es) | 2017-02-22 | 2022-05-04 | Método para formular un polipéptido terapéutico de unión a pcsk9 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180100397A AR110938A1 (es) | 2017-02-22 | 2018-02-20 | Formulaciones de evolocumab de alta concentración y baja viscosidad y métodos para elaborarlas |
Country Status (17)
Country | Link |
---|---|
US (2) | US11464857B2 (es) |
EP (1) | EP3585821A1 (es) |
JP (1) | JP7377596B2 (es) |
KR (2) | KR20240060732A (es) |
CN (1) | CN110536906A (es) |
AR (2) | AR110938A1 (es) |
AU (1) | AU2018224095A1 (es) |
BR (1) | BR112019017393A8 (es) |
CA (1) | CA3053394A1 (es) |
CL (1) | CL2019002362A1 (es) |
EA (1) | EA201991951A1 (es) |
IL (1) | IL268515A (es) |
MA (1) | MA47601A (es) |
MX (1) | MX2019009952A (es) |
SG (1) | SG11201907505TA (es) |
UY (1) | UY37611A (es) |
WO (1) | WO2018156741A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA033444B1 (ru) | 2014-10-23 | 2019-10-31 | Amgen Inc | Снижение вязкости фармацевтических составов |
CN108239150A (zh) | 2016-12-24 | 2018-07-03 | 信达生物制药(苏州)有限公司 | 抗pcsk9抗体及其用途 |
JP7377596B2 (ja) | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
AU2020263318A1 (en) * | 2019-04-23 | 2021-10-21 | Amgen Inc. | The use of low molecular weight polyvinylpyrrolidone (PVP) to reduce viscosity of high concentration protein formulations |
WO2022217021A1 (en) * | 2021-04-09 | 2022-10-13 | Avantor Performance Materials, Llc | Performance-enhancing excipients and methods of reducing viscosity and increasing stability of biologic formulations |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5078997A (en) | 1988-07-13 | 1992-01-07 | Cetus Corporation | Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers |
US5955448A (en) | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
US6767892B1 (en) | 1997-11-07 | 2004-07-27 | Chrion Corporation | Compositions providing for increased IGF-I solubility |
WO2002038170A2 (en) | 2000-11-07 | 2002-05-16 | Chiron Corporation | Stabilized inteferon compositions |
JP4583762B2 (ja) | 2002-02-27 | 2010-11-17 | イミュネックス・コーポレーション | ポリペプチド製剤 |
AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
CA2512174A1 (en) | 2003-01-30 | 2004-08-12 | Christian B. Allan | Anti-integrin .alpha..nu..beta.3 antibody formulations and uses thereof |
ZA200507757B (en) | 2003-04-04 | 2007-01-31 | Genentech Inc | High concentration antibody and protein formulations |
US20060051347A1 (en) | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
WO2007074880A1 (ja) | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
TWI516501B (zh) * | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9拮抗劑類 |
BR112012011539A8 (pt) | 2009-11-17 | 2017-12-26 | Ipsen Pharma Sas | formulação para a combinação de hgh e rhigf-1 |
SI3409289T1 (sl) | 2010-02-26 | 2020-12-31 | Novo Nordisk A/S | Stabilni sestavki, ki vsebujejo protitelo |
JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
WO2013012022A1 (ja) | 2011-07-19 | 2013-01-24 | 中外製薬株式会社 | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 |
EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
WO2013186230A1 (en) | 2012-06-12 | 2013-12-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulation for a therapeutic antibody |
US20150004174A1 (en) * | 2013-06-28 | 2015-01-01 | Amgen Inc. | Methods for treating homozygous familial hypercholesterolemia |
TWI694836B (zh) | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
EA033444B1 (ru) | 2014-10-23 | 2019-10-31 | Amgen Inc | Снижение вязкости фармацевтических составов |
MX2017007156A (es) | 2014-12-03 | 2017-08-28 | Csl Behring Ag | Producto farmaceutico con estabilidad incrementada que comprende inmunoglobulinas. |
SG10201912565QA (en) | 2016-09-29 | 2020-02-27 | Amgen Inc | Low-viscosity antigen binding proteins and methods of making them |
EP3522918A1 (en) | 2016-10-06 | 2019-08-14 | Amgen Inc. | Reduced viscosity protein pharmaceutical formulations |
JP7377596B2 (ja) | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
-
2018
- 2018-02-14 JP JP2018023742A patent/JP7377596B2/ja active Active
- 2018-02-20 AR ARP180100397A patent/AR110938A1/es unknown
- 2018-02-20 UY UY0001037611A patent/UY37611A/es unknown
- 2018-02-22 CA CA3053394A patent/CA3053394A1/en active Pending
- 2018-02-22 CN CN201880025966.7A patent/CN110536906A/zh active Pending
- 2018-02-22 SG SG11201907505TA patent/SG11201907505TA/en unknown
- 2018-02-22 KR KR1020247014122A patent/KR20240060732A/ko active Search and Examination
- 2018-02-22 EA EA201991951A patent/EA201991951A1/ru unknown
- 2018-02-22 AU AU2018224095A patent/AU2018224095A1/en active Pending
- 2018-02-22 US US15/902,775 patent/US11464857B2/en active Active
- 2018-02-22 MX MX2019009952A patent/MX2019009952A/es unknown
- 2018-02-22 BR BR112019017393A patent/BR112019017393A8/pt unknown
- 2018-02-22 WO PCT/US2018/019189 patent/WO2018156741A1/en unknown
- 2018-02-22 KR KR1020197026969A patent/KR20190120257A/ko not_active IP Right Cessation
- 2018-02-22 MA MA047601A patent/MA47601A/fr unknown
- 2018-02-22 EP EP18710193.6A patent/EP3585821A1/en active Pending
-
2019
- 2019-08-05 IL IL268515A patent/IL268515A/en unknown
- 2019-08-21 CL CL2019002362A patent/CL2019002362A1/es unknown
-
2022
- 2022-05-04 AR ARP220101176A patent/AR125766A2/es unknown
- 2022-08-23 US US17/893,515 patent/US20230226177A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230226177A1 (en) | 2023-07-20 |
JP7377596B2 (ja) | 2023-11-10 |
JP2018154616A (ja) | 2018-10-04 |
US11464857B2 (en) | 2022-10-11 |
CA3053394A1 (en) | 2018-08-30 |
MX2019009952A (es) | 2019-10-14 |
TW201841650A (zh) | 2018-12-01 |
KR20240060732A (ko) | 2024-05-08 |
CL2019002362A1 (es) | 2019-11-29 |
EA201991951A1 (ru) | 2020-01-21 |
EP3585821A1 (en) | 2020-01-01 |
CN110536906A (zh) | 2019-12-03 |
BR112019017393A2 (pt) | 2020-04-14 |
AU2018224095A1 (en) | 2019-08-22 |
US20180237501A1 (en) | 2018-08-23 |
IL268515A (en) | 2019-09-26 |
KR20190120257A (ko) | 2019-10-23 |
UY37611A (es) | 2018-08-31 |
SG11201907505TA (en) | 2019-09-27 |
WO2018156741A1 (en) | 2018-08-30 |
BR112019017393A8 (pt) | 2022-03-03 |
AR110938A1 (es) | 2019-05-15 |
MA47601A (fr) | 2020-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR125766A2 (es) | Método para formular un polipéptido terapéutico de unión a pcsk9 | |
US11453714B2 (en) | Human antibodies to influenza hemagglutinin | |
PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
JP6309521B2 (ja) | pH依存性結合特性を有する抗PCSK9抗体 | |
AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
US9265827B2 (en) | Anti-PDGFR-beta antibodies and uses thereof | |
US20180222976A1 (en) | Anti-ASIC1 Antibodies and Uses Thereof | |
ECSP17005649A (es) | Anticuerpos anti-tau humanizados | |
PE20210180A1 (es) | Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos | |
PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
PE20170900A1 (es) | Metodos y formulaciones para tratar enfermedades vasculares de los ojos | |
PE20141432A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
PE20181052A1 (es) | Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9 | |
AR110719A1 (es) | Anticuerpos humanos a la toxina hemolisina a de s. aureus | |
AR052959A1 (es) | Anticuerpos anti- ccr5 y usos de los mismos | |
AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
JP6761142B1 (ja) | 改良された血液凝固促進抗体 | |
AR123480A1 (es) | Moléculas de unión terapéuticas | |
RU2021128024A (ru) | Способы культивирования клеток | |
AR121898A1 (es) | Compuestos y métodos dirigidos a interleucina-34 | |
US20210238306A1 (en) | Procoagulant antibodies | |
RU2015125343A (ru) | Гуманизированные моноклональные антитела против активированного белка с и их применение | |
US9371383B2 (en) | Anti-ASIC1 antibodies and uses thereof | |
US20150266957A1 (en) | Anti-Prokineticin Receptor (PROKR) Antibodies and Uses Thereof | |
AR125226A1 (es) | Anticuerpos anti-tau y usos de estos |